Biocorrx (OTCMKTS:BICX – Get Free Report) will likely be releasing its resultson Monday, August 17th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $0.24 million for the quarter.
Biocorrx (OTCMKTS:BICX – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.22 million.
Biocorrx Price Performance
OTCMKTS:BICX opened at $0.30 on Monday. Biocorrx has a one year low of $0.20 and a one year high of $1.28. The business has a fifty day moving average price of $0.33 and a 200-day moving average price of $0.35. The firm has a market capitalization of $8.84 million, a price-to-earnings ratio of -1.86 and a beta of 0.19.
About Biocorrx
BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.
Featured Stories
- Five stocks we like better than Biocorrx
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
